Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum BioExx Specialty Proteins Ltd BIXZF

"Bioexx Specialty Proteins Inc is engaged in the development and commercialization of processing technologies, for use in the extracting various active ingredients from organic and inorganic materials. The company's primary focus is on the production of proteins from canola and other oilseed feedstocks. Its products include Isolexx, a protein isolate for use in bakery products, meat products... see more

GREY:BIXZF - Post Discussion

View:
Post by marcus771 on Dec 04, 2013 12:29pm

Value

Clearly trying to sell a company that wasn't approved before would be a hard sell. Now they have potential and huge bargaining chip when the EU has found Isolexx safe for human consumption. Whoever does purchase this patent will be laughing in 3-4 months when it gets the final nod.
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities